---
title: "ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285514962.md"
description: "ZeJing Pharma announced that its injectable human thyrotropin beta has met the primary endpoint in its Phase III clinical trial for differentiated thyroid cancer. The trial demonstrated expected efficacy and safety results. The company plans to submit a Pre-BLA communication application to the CDE to advance the market approval process. Detailed data will be presented at future clinical academic conferences."
datetime: "2026-05-07T08:43:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285514962.md)
  - [en](https://longbridge.com/en/news/285514962.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285514962.md)
---

# ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary Endpoint

ZeJing Pharma announced on May 7 that its independently developed injectable human thyrotropin beta has achieved the primary endpoint in its Phase III clinical trial. According to Jin10, the study, titled 'Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Study on the Efficacy and Safety of Recombinant Human Thyrotropin in Postoperative Radioiodine Therapy for Differentiated Thyroid Cancer Patients,' demonstrated expected efficacy and safety results. The trial met the pre-set primary endpoint. The company plans to submit a Pre-BLA communication application to the CDE to actively advance the market approval process for this indication. Detailed data from the study will be presented at future international or domestic clinical academic conferences.

### Related Stocks

- [688266.CN](https://longbridge.com/en/quote/688266.CN.md)

## Related News & Research

- [MAA Announces Quarterly Common Dividend | MAA Stock News](https://longbridge.com/en/news/286961140.md)
- [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)